Morphic Medical Achieves NUB Status One for RESET Endoscopic Therapy in Germany
Morphic Medical, a pioneer in medical technology, recently announced a significant milestone for its innovative therapy, RESET®, having achieved NUB Status One in Germany. This designation is pivotal for the adoption of RESET, an endoscopic treatment specifically engineered to address severe obesity and Type 2 diabetes through a minimally invasive approach. The accomplishment of NUB Status One permits German hospitals to seek additional reimbursements when utilizing the RESET therapy, facilitating wider implementation and commercialization.
The RESET system offers patients a surgical alternative, providing an incision-free procedure that aims to induce immediate weight reduction and improve metabolic disorders. As a result of extensive clinical evaluations, RESET has been recognized for its safety, efficacy, and sustained health benefits. These evaluations are grounded in a substantial collection of peer-reviewed publications, real-world data, and clinical experiences that substantiate the advantages of the duodenojejunal bypass for individuals struggling with obesity and diabetes.
Mike Gutteridge, the CEO of Morphic Medical, emphasized the significance of the NUB recognition, stating, "This acknowledgment is a major achievement for Morphic Medical, as well as for patients and hospitals seeking evidence-based endoscopic metabolic therapies." He further expounded that this status reflects a comprehensive and credible compilation of data amassed through years of clinical research and practical application, thereby strengthening constructive dialogues with German healthcare centers and enhancing confidence in RESET as a clinically impactful solution.
Following the NUB designation, Morphic Medical plans to collaborate with leading hospitals in Germany to support individual NUB requests, which will broaden the therapy’s clinical adoption across the region. The company remains diligent in its commitment to post-market clinical follow-ups, participating in registries, and generating further evidence to advocate for long-term reimbursement and incorporation into medical guidelines.
For those unfamiliar, Morphic Medical is distinguished for developing RESET, a groundbreaking endoscopic therapy that presents a non-surgical treatment option for patients facing morbid obesity and concurrent cardiometabolic risks, such as Type 2 diabetes or dyslipidemia. It is important to note that while RESET shows promise, it is currently not approved for sale in the United States, with its application being restricted solely to research-related purposes under federal law.
Established in 2003 and headquartered in Boston, Massachusetts, Morphic Medical sets out to revolutionize the realm of obesity treatment and metabolic health through innovative technologies. For more details on their approach, products, or ongoing studies, visit morphicmedical.com or follow them on Twitter and LinkedIn.
The RESET system offers patients a surgical alternative, providing an incision-free procedure that aims to induce immediate weight reduction and improve metabolic disorders. As a result of extensive clinical evaluations, RESET has been recognized for its safety, efficacy, and sustained health benefits. These evaluations are grounded in a substantial collection of peer-reviewed publications, real-world data, and clinical experiences that substantiate the advantages of the duodenojejunal bypass for individuals struggling with obesity and diabetes.
Mike Gutteridge, the CEO of Morphic Medical, emphasized the significance of the NUB recognition, stating, "This acknowledgment is a major achievement for Morphic Medical, as well as for patients and hospitals seeking evidence-based endoscopic metabolic therapies." He further expounded that this status reflects a comprehensive and credible compilation of data amassed through years of clinical research and practical application, thereby strengthening constructive dialogues with German healthcare centers and enhancing confidence in RESET as a clinically impactful solution.
Following the NUB designation, Morphic Medical plans to collaborate with leading hospitals in Germany to support individual NUB requests, which will broaden the therapy’s clinical adoption across the region. The company remains diligent in its commitment to post-market clinical follow-ups, participating in registries, and generating further evidence to advocate for long-term reimbursement and incorporation into medical guidelines.
For those unfamiliar, Morphic Medical is distinguished for developing RESET, a groundbreaking endoscopic therapy that presents a non-surgical treatment option for patients facing morbid obesity and concurrent cardiometabolic risks, such as Type 2 diabetes or dyslipidemia. It is important to note that while RESET shows promise, it is currently not approved for sale in the United States, with its application being restricted solely to research-related purposes under federal law.
Established in 2003 and headquartered in Boston, Massachusetts, Morphic Medical sets out to revolutionize the realm of obesity treatment and metabolic health through innovative technologies. For more details on their approach, products, or ongoing studies, visit morphicmedical.com or follow them on Twitter and LinkedIn.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.